
@ARTICLE{Tran2016-ml,
  title         = "Edward: A library for probabilistic modeling, inference, and
                   criticism",
  author        = "Tran, Dustin and Kucukelbir, Alp and Dieng, Adji B and
                   Rudolph, Maja and Liang, Dawen and Blei, David M",
  abstract      = "Probabilistic modeling is a powerful approach for analyzing
                   empirical information. We describe Edward, a library for
                   probabilistic modeling. Edward's design reflects an
                   iterative process pioneered by George Box: build a model of
                   a phenomenon, make inferences about the model given data,
                   and criticize the model's fit to the data. Edward supports a
                   broad class of probabilistic models, efficient algorithms
                   for inference, and many techniques for model criticism. The
                   library builds on top of TensorFlow to support distributed
                   training and hardware such as GPUs. Edward enables the
                   development of complex probabilistic models and their
                   algorithms at a massive scale.",
  month         =  "31~" # oct,
  year          =  2016,
  archivePrefix = "arXiv",
  primaryClass  = "stat.CO",
  eprint        = "1610.09787"
}


@ARTICLE{Campbell2016-nu,
  title         = "Stratification of patient trajectories using covariate
                   latent variable models",
  author        = "Campbell, Kieran R and Yau, Christopher",
  abstract      = "Standard models assign disease progression to discrete
                   categories or stages based on well-characterized clinical
                   markers. However, such a system is potentially at odds with
                   our understanding of the underlying biology, which in highly
                   complex systems may support a (near-)continuous evolution of
                   disease from inception to terminal state. To learn such a
                   continuous disease score one could infer a latent variable
                   from dynamic ``omics'' data such as RNA-seq that correlates
                   with an outcome of interest such as survival time. However,
                   such analyses may be confounded by additional data such as
                   clinical covariates measured in electronic health records
                   (EHRs). As a solution to this we introduce covariate latent
                   variable models, a novel type of latent variable model that
                   learns a low-dimensional data representation in the presence
                   of two (asymmetric) views of the same data source. We apply
                   our model to TCGA colorectal cancer RNA-seq data and
                   demonstrate how incorporating microsatellite-instability
                   (MSI) status as an external covariate allows us to identify
                   genes that stratify patients on an immune-response
                   trajectory. Finally, we propose an extension termed
                   Covariate Gaussian Process Latent Variable Models for
                   learning nonparametric, nonlinear representations. An R
                   package implementing variational inference for covariate
                   latent variable models is available at
                   http://github.com/kieranrcampbell/clvm.",
  month         =  "27~" # oct,
  year          =  2016,
  archivePrefix = "arXiv",
  primaryClass  = "stat.ML",
  eprint        = "1610.08735"
}


@ARTICLE{Kingma2013-wo,
  title         = "{Auto-Encoding} Variational Bayes",
  author        = "Kingma, Diederik P and Welling, Max",
  abstract      = "How can we perform efficient inference and learning in
                   directed probabilistic models, in the presence of continuous
                   latent variables with intractable posterior distributions,
                   and large datasets? We introduce a stochastic variational
                   inference and learning algorithm that scales to large
                   datasets and, under some mild differentiability conditions,
                   even works in the intractable case. Our contributions is
                   two-fold. First, we show that a reparameterization of the
                   variational lower bound yields a lower bound estimator that
                   can be straightforwardly optimized using standard stochastic
                   gradient methods. Second, we show that for i.i.d. datasets
                   with continuous latent variables per datapoint, posterior
                   inference can be made especially efficient by fitting an
                   approximate inference model (also called a recognition
                   model) to the intractable posterior using the proposed lower
                   bound estimator. Theoretical advantages are reflected in
                   experimental results.",
  month         =  "20~" # dec,
  year          =  2013,
  archivePrefix = "arXiv",
  primaryClass  = "stat.ML",
  eprint        = "1312.6114v10"
}


@ARTICLE{Weinstein2013-ww,
  title     = "The cancer genome atlas pan-cancer analysis project",
  author    = "Weinstein, John N and Collisson, Eric A and Mills, Gordon B and
               Shaw, Kenna R Mills and Ozenberger, Brad A and Ellrott, Kyle and
               Shmulevich, Ilya and Sander, Chris and Stuart, Joshua M and
               Network, Cancer Genome Atlas Research and {Others}",
  journal   = "Nat. Genet.",
  publisher = "Nature Publishing Group",
  volume    =  45,
  number    =  10,
  pages     = "1113--1120",
  year      =  2013
}


@ARTICLE{Law2014-tu,
  title    = "voom: Precision weights unlock linear model analysis tools for
              {RNA-seq} read counts",
  author   = "Law, Charity W and Chen, Yunshun and Shi, Wei and Smyth, Gordon K",
  abstract = "New normal linear modeling strategies are presented for analyzing
              read counts from RNA-seq experiments. The voom method estimates
              the mean-variance relationship of the log-counts, generates a
              precision weight for each observation and enters these into the
              limma empirical Bayes analysis pipeline. This opens access for
              RNA-seq analysts to a large body of methodology developed for
              microarrays. Simulation studies show that voom performs as well
              or better than count-based RNA-seq methods even when the data are
              generated according to the assumptions of the earlier methods.
              Two case studies illustrate the use of linear modeling and gene
              set testing methods.",
  journal  = "Genome Biol.",
  volume   =  15,
  number   =  2,
  pages    = "R29",
  month    =  "3~" # feb,
  year     =  2014,
  language = "en"
}


@ARTICLE{Pimentel2016-xz,
  title     = "Differential analysis of {RNA-Seq} incorporating quantification
               uncertainty",
  author    = "Pimentel, H J and Bray, N and Puente, S and Melsted, P and
               Pachter, L",
  abstract  = "Abstract We describe a novel method for the differential
               analysis of RNA-Seq data that utilizes bootstrapping in
               conjunction with response error linear modeling to decouple
               biological variance from inferential variance. The method is
               implemented in an interactive shiny app called sleuth that
               utilizes kallisto quantifications and bootstraps for fast and
               accurate analysis of RNA-Seq experiments.",
  journal   = "bioRxiv",
  publisher = "biorxiv.org",
  year      =  2016
}


@ARTICLE{Katzman2016-jp,
  title         = "Deep Survival: A Deep Cox Proportional Hazards Network",
  author        = "Katzman, Jared and Shaham, Uri and Bates, Jonathan and
                   Cloninger, Alexander and Jiang, Tingting and Kluger, Yuval",
  abstract      = "Previous research has shown that neural networks can model
                   survival data in situations in which some patients' death
                   times are unknown, e.g. right-censored. However, neural
                   networks have rarely been shown to outperform their linear
                   counterparts such as the Cox proportional hazards model. In
                   this paper, we run simulated experiments and use real
                   survival data to build upon the risk-regression architecture
                   proposed by Faraggi and Simon. We demonstrate that our
                   model, DeepSurv, not only works as well as other survival
                   models but actually outperforms in predictive ability on
                   survival data with linear and nonlinear risk functions. We
                   then show that the neural network can also serve as a
                   recommender system by including a categorical variable
                   representing a treatment group. This can be used to provide
                   personalized treatment recommendations based on an
                   individual's calculated risk. We provide an open source
                   Python module that implements these methods in order to
                   advance research on deep learning and survival analysis.",
  month         =  "2~" # jun,
  year          =  2016,
  archivePrefix = "arXiv",
  primaryClass  = "stat.ML",
  eprint        = "1606.00931"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@INPROCEEDINGS{Ranganath2016-kn,
  title      = "Deep Survival Analysis",
  booktitle  = "Machine Learning for Healthcare Conference",
  author     = "Ranganath, Rajesh and Perotte, Adler and Elhadad, No{\'e}mie
                and Blei, David",
  abstract   = "Disparate areas of machine learning have benefited from models
                that can take raw data with little preprocessing as input and
                learn rich representations of that raw data in order to perform
                well on a given prediction task. We evaluate this approach in
                healthcare by using longitudinal measurements of lab tests, one
                of the more raw signals of a patientâ€™s health state widely
                available in clinical data, to predict disease onsets. In
                particular, we train a Long Short-Term Memory (LSTM) recurrent
                neural network and two novel convolutional neural networks for
                multi-task prediction of disease onset for 133 conditions based
                on 18 common lab tests measured over time in a cohort of 298K
                patients derived from 8 years of administrative claims data. We
                compare the neural networks to a logistic regression with
                several hand-engineered, clinically relevant features. We find
                that the representation-based learning approaches significantly
                outperform this baseline. We believe that our work suggests a
                new avenue for patient risk stratification based solely on lab
                results.",
  pages      = "101--114",
  month      =  "10~" # dec,
  year       =  2016,
  language   = "en",
  conference = "Machine Learning for Healthcare Conference"
}

@INPROCEEDINGS{Schulam2016-sj,
  title     = "Disease Trajectory Maps",
  booktitle = "Advances In Neural Information Processing Systems",
  author    = "Schulam, Peter and Arora, Raman",
  pages     = "4709--4717",
  year      =  2016
}


@ARTICLE{Lawrence2005-cu,
  title    = "Probabilistic Non-linear Principal Component Analysis with
              Gaussian Process Latent Variable Models",
  author   = "Lawrence, Neil",
  journal  = "J. Mach. Learn. Res.",
  volume   =  6,
  number   = "Nov",
  pages    = "1783--1816",
  year     =  2005
}

@article{tatlow2016cloud,
  title={A cloud-based workflow to quantify transcript-expression levels in public cancer compendia},
  author={Tatlow, PJ and Piccolo, Stephen R},
  journal={bioRxiv},
  pages={063552},
  year={2016},
  publisher={Cold Spring Harbor Labs Journals}
}

@article{blei2016variational,
  title={Variational inference: A review for statisticians},
  author={Blei, David M and Kucukelbir, Alp and McAuliffe, Jon D},
  journal={arXiv preprint arXiv:1601.00670},
  year={2016}
}


@ARTICLE{Naderi2007-mb,
  title       = "A gene-expression signature to predict survival in breast
                 cancer across independent data sets",
  author      = "Naderi, A and Teschendorff, A E and Barbosa-Morais, N L and
                 Pinder, S E and Green, A R and Powe, D G and Robertson, J F R
                 and Aparicio, S and Ellis, I O and Brenton, J D and Caldas, C",
  affiliation = "Cancer Genomics Program, Department of Oncology, Hutchison/MRC
                 Research Center, University of Cambridge, Cambridge, UK.",
  abstract    = "Prognostic signatures in breast cancer derived from microarray
                 expression profiling have been reported by two independent
                 groups. These signatures, however, have not been validated in
                 external studies, making clinical application problematic. We
                 performed microarray expression profiling of 135 early-stage
                 tumors, from a cohort representative of the demographics of
                 breast cancer. Using a recently proposed semisupervised
                 method, we identified a prognostic signature of 70 genes that
                 significantly correlated with survival (hazard ratio (HR):
                 5.97, 95\% confidence interval: 3.0-11.9, P = 2.7e-07). In
                 multivariate analysis, the signature performed independently
                 of other standard prognostic classifiers such as the
                 Nottingham Prognostic Index and the 'Adjuvant!' software.
                 Using two different prognostic classification schemes and
                 measures, nearest centroid (HR) and risk ordering (D-index),
                 the 70-gene classifier was also found to be prognostic in two
                 independent external data sets. Overall, the 70-gene set was
                 prognostic in our study and the two external studies which
                 collectively include 715 patients. In contrast, we found that
                 the two previously described prognostic gene sets performed
                 less optimally in external validation. Finally, a common
                 prognostic module of 29 genes that associated with survival in
                 both our cohort and the two external data sets was identified.
                 In spite of these results, further studies that profile larger
                 cohorts using a single microarray platform, will be needed
                 before prospective clinical use of molecular classifiers can
                 be contemplated.",
  journal     = "Oncogene",
  volume      =  26,
  number      =  10,
  pages       = "1507--1516",
  month       =  "1~" # mar,
  year        =  2007,
  language    = "en"
}

@ARTICLE{Aguirre-Gamboa2013-ku,
  title       = "{SurvExpress}: an online biomarker validation tool and
                 database for cancer gene expression data using survival
                 analysis",
  author      = "Aguirre-Gamboa, Raul and Gomez-Rueda, Hugo and
                 Mart{\'\i}nez-Ledesma, Emmanuel and Mart{\'\i}nez-Torteya,
                 Antonio and Chacolla-Huaringa, Rafael and
                 Rodriguez-Barrientos, Alberto and Tamez-Pe{\~n}a, Jos{\'e} G
                 and Trevi{\~n}o, Victor",
  affiliation = "C{\'a}tedra de Bioinform{\'a}tica, Tecnol{\'o}gico de
                 Monterrey, Monterrey, Nuevo Le{\'o}n, M{\'e}xico.",
  abstract    = "Validation of multi-gene biomarkers for clinical outcomes is
                 one of the most important issues for cancer prognosis. An
                 important source of information for virtual validation is the
                 high number of available cancer datasets. Nevertheless,
                 assessing the prognostic performance of a gene expression
                 signature along datasets is a difficult task for Biologists
                 and Physicians and also time-consuming for Statisticians and
                 Bioinformaticians. Therefore, to facilitate performance
                 comparisons and validations of survival biomarkers for cancer
                 outcomes, we developed SurvExpress, a cancer-wide gene
                 expression database with clinical outcomes and a web-based
                 tool that provides survival analysis and risk assessment of
                 cancer datasets. The main input of SurvExpress is only the
                 biomarker gene list. We generated a cancer database collecting
                 more than 20,000 samples and 130 datasets with censored
                 clinical information covering tumors over 20 tissues. We
                 implemented a web interface to perform biomarker validation
                 and comparisons in this database, where a multivariate
                 survival analysis can be accomplished in about one minute. We
                 show the utility and simplicity of SurvExpress in two
                 biomarker applications for breast and lung cancer. Compared to
                 other tools, SurvExpress is the largest, most versatile, and
                 quickest free tool available. SurvExpress web can be accessed
                 in http://bioinformatica.mty.itesm.mx/SurvExpress (a tutorial
                 is included). The website was implemented in JSP, JavaScript,
                 MySQL, and R.",
  journal     = "PLoS One",
  volume      =  8,
  number      =  9,
  pages       = "e74250",
  month       =  "16~" # sep,
  year        =  2013,
  language    = "en"
}

@ARTICLE{Goswami2013-ar,
  title       = "{PROGgene}: gene expression based survival analysis web
                 application for multiple cancers",
  author      = "Goswami, Chirayu Pankaj and Nakshatri, Harikrishna",
  affiliation = "Thomas Jefferson University Hospitals, 117 S 11th Street,
                 Suite 207, Philadelphia, PA 19107, USA.
                 chirayu.goswami@jeffersonhospital.org.",
  abstract    = "BACKGROUND: Identification of prognostic mRNA biomarkers has
                 been done for various cancer types. The data that are
                 published from such studies are archived in public
                 repositories. There are hundreds of such datasets available
                 for multiple cancer types in public repositories. Wealth of
                 such data can be utilized to study prognostic implications of
                 mRNA in different cancers as well as in different populations
                 or subtypes of same cancer. DESCRIPTION: We have created a web
                 application that can be used for studying prognostic
                 implications of mRNA biomarkers in a variety of cancers. We
                 have compiled data from public repositories such as GEO, EBI
                 Array Express and The Cancer Genome Atlas for creating this
                 tool. With 64 patient series from 18 cancer types in our
                 database, this tool provides the most comprehensive resource
                 available for survival analysis to date. The tool is called
                 PROGgene and it is available at
                 http://www.compbio.iupui.edu/proggene. CONCLUSIONS: We present
                 this tool as a hypothesis generation tool for researchers to
                 identify potential prognostic mRNA biomarkers to follow up
                 with further research. For this reason, we have kept the web
                 application very simple and straightforward. We believe this
                 tool will be useful in accelerating biomarker discovery in
                 cancer and quickly providing results that may indicate
                 disease-specific prognostic value of specific biomarkers.",
  journal     = "J. Clin. Bioinforma.",
  volume      =  3,
  number      =  1,
  pages       = "22",
  month       =  "28~" # oct,
  year        =  2013,
  language    = "en"
}

@article{verhaak2010integrated,
  title={Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1},
  author={Verhaak, Roel GW and Hoadley, Katherine A and Purdom, Elizabeth and Wang, Victoria and Qi, Yuan and Wilkerson, Matthew D and Miller, C Ryan and Ding, Li and Golub, Todd and Mesirov, Jill P and others},
  journal={Cancer cell},
  volume={17},
  number={1},
  pages={98--110},
  year={2010},
  publisher={Elsevier}
}

@article{ceccarelli2016molecular,
  title={Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma},
  author={Ceccarelli, Michele and Barthel, Floris P and Malta, Tathiane M and Sabedot, Thais S and Salama, Sofie R and Murray, Bradley A and Morozova, Olena and Newton, Yulia and Radenbaugh, Amie and Pagnotta, Stefano M and others},
  journal={Cell},
  volume={164},
  number={3},
  pages={550--563},
  year={2016},
  publisher={Elsevier}
}


@ARTICLE{Chen2007-ql,
  title    = "A {Five-Gene} Signature and Clinical Outcome in {Non--Small-Cell}
              Lung Cancer",
  author   = "Chen, Hsuan-Yu and Yu, Sung-Liang and Chen, Chun-Houh and Chang,
              Gee-Chen and Chen, Chih-Yi and Yuan, Ang and Cheng, Chiou-Ling
              and Wang, Chien-Hsun and Terng, Harn-Jing and Kao, Shu-Fang and
              Chan, Wing-Kai and Li, Han-Ni and Liu, Chun-Chi and Singh, Sher
              and Chen, Wei J and Chen, Jeremy J W and Yang, Pan-Chyr",
  abstract = "Lung cancer --- predominantly non--small-cell lung cancer (NSCLC)
              --- is the most common cause of death from cancer worldwide.1 The
              relapse rate among patients with early-stage NSCLC is 40\% within
              5 years after potentially curative treatment.2 The current
              staging system for NSCLC is inadequate for predicting the outcome
              of treatment. Gene-expression profiling (see Glossary) by means
              of microarrays3,4 and reverse-transcriptase polymerase chain
              reaction (RT-PCR)5,6 is useful for classifying tumors and
              formulating a prognosis for patients with various types of
              cancer,7--9 including lung cancer.10--16 The use of microarrays
              in clinical practice is limited, however, by the large . . .",
  journal  = "N. Engl. J. Med.",
  volume   =  356,
  number   =  1,
  pages    = "11--20",
  year     =  2007
}

@ARTICLE{Newhook2014-kc,
  title       = "A thirteen-gene expression signature predicts survival of
                 patients with pancreatic cancer and identifies new genes of
                 interest",
  author      = "Newhook, Timothy E and Blais, Edik M and Lindberg, James M and
                 Adair, Sara J and Xin, Wenjun and Lee, Jae K and Papin, Jason
                 A and Parsons, J Thomas and Bauer, Todd W",
  affiliation = "Department of Surgery, University of Virginia,
                 Charlottesville, Virginia, United States of America.
                 Department of Biomedical Engineering, University of Virginia,
                 Charlottesville, Virginia, United States of America.
                 Department of Surgery, University of Virginia,
                 Charlottesville, Virginia, United States of America.
                 Department of Surgery, University of Virginia,
                 Charlottesville, Virginia, United States of America.
                 Department of Public Health Sciences, University of Virginia,
                 Charlottesville, Virginia, United States of America.
                 Department of Public Health Sciences, University of Virginia,
                 Charlottesville, Virginia, United States of America.
                 Department of Biomedical Engineering, University of Virginia,
                 Charlottesville, Virginia, United States of America.
                 Department of Microbiology, Immunology, and Cancer Biology,
                 University of Virginia, Charlottesville, Virginia, United
                 States of America. Department of Surgery, University of
                 Virginia, Charlottesville, Virginia, United States of America.",
  abstract    = "BACKGROUND: Currently, prognostication for pancreatic ductal
                 adenocarcinoma (PDAC) is based upon a coarse clinical staging
                 system. Thus, more accurate prognostic tests are needed for
                 PDAC patients to aid treatment decisions. METHODS AND
                 FINDINGS: Affymetrix gene expression profiling was carried out
                 on 15 human PDAC tumors and from the data we identified a
                 13-gene expression signature (risk score) that correlated with
                 patient survival. The gene expression risk score was then
                 independently validated using published gene expression data
                 and survival data for an additional 101 patients with
                 pancreatic cancer. Patients with high-risk scores had
                 significantly higher risk of death compared to patients with
                 low-risk scores (HR 2.27, p = 0.002). When the 13-gene score
                 was combined with lymph node status the risk-score further
                 discriminated the length of patient survival time (p<0.001).
                 Patients with a high-risk score had poor survival independent
                 of nodal status; however, nodal status increased
                 predictability for survival in patients with a low-risk gene
                 signature score (low-risk N1 vs. low-risk N0: HR = 2.0, p =
                 0.002). While AJCC stage correlated with patient survival (p =
                 0.03), the 13-gene score was superior at predicting survival.
                 Of the 13 genes comprising the predictive model, four have
                 been shown to be important in PDAC, six are unreported in PDAC
                 but important in other cancers, and three are unreported in
                 any cancer. CONCLUSIONS: We identified a 13-gene expression
                 signature that predicts survival of PDAC patients and could
                 prove useful for making treatment decisions. This risk score
                 should be evaluated prospectively in clinical trials for
                 prognostication and for predicting response to chemotherapy.
                 Investigation of new genes identified in our model may lead to
                 novel therapeutic targets.",
  journal     = "PLoS One",
  volume      =  9,
  number      =  9,
  pages       = "e105631",
  month       =  "2~" # sep,
  year        =  2014,
  language    = "en"
}

@ARTICLE{Beer2002-wm,
  title       = "Gene-expression profiles predict survival of patients with
                 lung adenocarcinoma",
  author      = "Beer, David G and Kardia, Sharon L R and Huang, Chiang-Ching
                 and Giordano, Thomas J and Levin, Albert M and Misek, David E
                 and Lin, Lin and Chen, Guoan and Gharib, Tarek G and Thomas,
                 Dafydd G and Lizyness, Michelle L and Kuick, Rork and
                 Hayasaka, Satoru and Taylor, Jeremy M G and Iannettoni, Mark D
                 and Orringer, Mark B and Hanash, Samir",
  affiliation = "Department of Surgery, University of Michigan, Ann Arbor,
                 Michigan, USA. dgbeer@umich.edu",
  abstract    = "Histopathology is insufficient to predict disease progression
                 and clinical outcome in lung adenocarcinoma. Here we show that
                 gene-expression profiles based on microarray analysis can be
                 used to predict patient survival in early-stage lung
                 adenocarcinomas. Genes most related to survival were
                 identified with univariate Cox analysis. Using either two
                 equivalent but independent training and testing sets, or
                 'leave-one-out' cross-validation analysis with all tumors, a
                 risk index based on the top 50 genes identified low-risk and
                 high-risk stage I lung adenocarcinomas, which differed
                 significantly with respect to survival. This risk index was
                 then validated using an independent sample of lung
                 adenocarcinomas that predicted high- and low-risk groups. This
                 index included genes not previously associated with survival.
                 The identification of a set of genes that predict survival in
                 early-stage lung adenocarcinoma allows delineation of a
                 high-risk group that may benefit from adjuvant therapy.",
  journal     = "Nat. Med.",
  volume      =  8,
  number      =  8,
  pages       = "816--824",
  month       =  aug,
  year        =  2002,
  language    = "en"
}


@ARTICLE{Patel2014-uu,
  title       = "Single-cell {RNA-seq} highlights intratumoral heterogeneity in
                 primary glioblastoma",
  author      = "Patel, Anoop P and Tirosh, Itay and Trombetta, John J and
                 Shalek, Alex K and Gillespie, Shawn M and Wakimoto, Hiroaki
                 and Cahill, Daniel P and Nahed, Brian V and Curry, William T
                 and Martuza, Robert L and Louis, David N and Rozenblatt-Rosen,
                 Orit and Suv{\`a}, Mario L and Regev, Aviv and Bernstein,
                 Bradley E",
  affiliation = "Department of Neurosurgery, Massachusetts General Hospital and
                 Harvard Medical School, Boston, MA 02114, USA. Department of
                 Pathology and Center for Cancer Research, Massachusetts
                 General Hospital and Harvard Medical School, Boston, MA 02114,
                 USA. Broad Institute of Harvard and Massachusetts Institute of
                 Techonology (MIT), Cambridge, MA 02142, USA. Howard Hughes
                 Medical Institute Chevy Chase, MD 20815, USA. Broad Institute
                 of Harvard and Massachusetts Institute of Techonology (MIT),
                 Cambridge, MA 02142, USA. Broad Institute of Harvard and
                 Massachusetts Institute of Techonology (MIT), Cambridge, MA
                 02142, USA. Broad Institute of Harvard and Massachusetts
                 Institute of Techonology (MIT), Cambridge, MA 02142, USA.
                 Department of Pathology and Center for Cancer Research,
                 Massachusetts General Hospital and Harvard Medical School,
                 Boston, MA 02114, USA. Broad Institute of Harvard and
                 Massachusetts Institute of Techonology (MIT), Cambridge, MA
                 02142, USA. Howard Hughes Medical Institute Chevy Chase, MD
                 20815, USA. Department of Neurosurgery, Massachusetts General
                 Hospital and Harvard Medical School, Boston, MA 02114, USA.
                 Department of Neurosurgery, Massachusetts General Hospital and
                 Harvard Medical School, Boston, MA 02114, USA. Department of
                 Neurosurgery, Massachusetts General Hospital and Harvard
                 Medical School, Boston, MA 02114, USA. Department of
                 Neurosurgery, Massachusetts General Hospital and Harvard
                 Medical School, Boston, MA 02114, USA. Department of
                 Neurosurgery, Massachusetts General Hospital and Harvard
                 Medical School, Boston, MA 02114, USA. Department of Pathology
                 and Center for Cancer Research, Massachusetts General Hospital
                 and Harvard Medical School, Boston, MA 02114, USA. Broad
                 Institute of Harvard and Massachusetts Institute of
                 Techonology (MIT), Cambridge, MA 02142, USA. Department of
                 Pathology and Center for Cancer Research, Massachusetts
                 General Hospital and Harvard Medical School, Boston, MA 02114,
                 USA. Broad Institute of Harvard and Massachusetts Institute of
                 Techonology (MIT), Cambridge, MA 02142, USA.
                 bernstein.bradley@mgh.harvard.edu aregev@broadinstitute.org
                 suva.mario@mgh.harvard.edu. Broad Institute of Harvard and
                 Massachusetts Institute of Techonology (MIT), Cambridge, MA
                 02142, USA. Howard Hughes Medical Institute Chevy Chase, MD
                 20815, USA. Department of Biology, MIT, Cambridge, MA 02139,
                 USA. bernstein.bradley@mgh.harvard.edu
                 aregev@broadinstitute.org suva.mario@mgh.harvard.edu.
                 Department of Pathology and Center for Cancer Research,
                 Massachusetts General Hospital and Harvard Medical School,
                 Boston, MA 02114, USA. Broad Institute of Harvard and
                 Massachusetts Institute of Techonology (MIT), Cambridge, MA
                 02142, USA. Howard Hughes Medical Institute Chevy Chase, MD
                 20815, USA. bernstein.bradley@mgh.harvard.edu
                 aregev@broadinstitute.org suva.mario@mgh.harvard.edu.",
  abstract    = "Human cancers are complex ecosystems composed of cells with
                 distinct phenotypes, genotypes, and epigenetic states, but
                 current models do not adequately reflect tumor composition in
                 patients. We used single-cell RNA sequencing (RNA-seq) to
                 profile 430 cells from five primary glioblastomas, which we
                 found to be inherently variable in their expression of diverse
                 transcriptional programs related to oncogenic signaling,
                 proliferation, complement/immune response, and hypoxia. We
                 also observed a continuum of stemness-related expression
                 states that enabled us to identify putative regulators of
                 stemness in vivo. Finally, we show that established
                 glioblastoma subtype classifiers are variably expressed across
                 individual cells within a tumor and demonstrate the potential
                 prognostic implications of such intratumoral heterogeneity.
                 Thus, we reveal previously unappreciated heterogeneity in
                 diverse regulatory programs central to glioblastoma biology,
                 prognosis, and therapy.",
  journal     = "Science",
  volume      =  344,
  number      =  6190,
  pages       = "1396--1401",
  month       =  "20~" # jun,
  year        =  2014,
  language    = "en"
}

@ARTICLE{Buettner2015-qq,
  title       = "Computational analysis of cell-to-cell heterogeneity in
                 single-cell {RNA-sequencing} data reveals hidden
                 subpopulations of cells",
  author      = "Buettner, Florian and Natarajan, Kedar N and Casale, F Paolo
                 and Proserpio, Valentina and Scialdone, Antonio and Theis,
                 Fabian J and Teichmann, Sarah A and Marioni, John C and
                 Stegle, Oliver",
  affiliation = "1] Helmholtz Zentrum M{\"u}nchen-German Research Center for
                 Environmental Health, Institute of Computational Biology,
                 Neuherberg, Germany. [2] European Molecular Biology
                 Laboratory, European Bioinformatics Institute, Wellcome Trust
                 Genome Campus, Hinxton, Cambridge, UK. 1] European Molecular
                 Biology Laboratory, European Bioinformatics Institute,
                 Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. [2]
                 Wellcome Trust Sanger Institute, Hinxton, UK. European
                 Molecular Biology Laboratory, European Bioinformatics
                 Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge,
                 UK. 1] European Molecular Biology Laboratory, European
                 Bioinformatics Institute, Wellcome Trust Genome Campus,
                 Hinxton, Cambridge, UK. [2] Wellcome Trust Sanger Institute,
                 Hinxton, UK. 1] European Molecular Biology Laboratory,
                 European Bioinformatics Institute, Wellcome Trust Genome
                 Campus, Hinxton, Cambridge, UK. [2] Wellcome Trust Sanger
                 Institute, Hinxton, UK. 1] Helmholtz Zentrum
                 M{\"u}nchen-German Research Center for Environmental Health,
                 Institute of Computational Biology, Neuherberg, Germany. [2]
                 Department of Mathematics, Technische Universit{\"a}t
                 M{\"u}nchen, Munich, Germany. 1] European Molecular Biology
                 Laboratory, European Bioinformatics Institute, Wellcome Trust
                 Genome Campus, Hinxton, Cambridge, UK. [2] Wellcome Trust
                 Sanger Institute, Hinxton, UK. 1] European Molecular Biology
                 Laboratory, European Bioinformatics Institute, Wellcome Trust
                 Genome Campus, Hinxton, Cambridge, UK. [2] Wellcome Trust
                 Sanger Institute, Hinxton, UK. European Molecular Biology
                 Laboratory, European Bioinformatics Institute, Wellcome Trust
                 Genome Campus, Hinxton, Cambridge, UK.",
  abstract    = "Recent technical developments have enabled the transcriptomes
                 of hundreds of cells to be assayed in an unbiased manner,
                 opening up the possibility that new subpopulations of cells
                 can be found. However, the effects of potential confounding
                 factors, such as the cell cycle, on the heterogeneity of gene
                 expression and therefore on the ability to robustly identify
                 subpopulations remain unclear. We present and validate a
                 computational approach that uses latent variable models to
                 account for such hidden factors. We show that our single-cell
                 latent variable model (scLVM) allows the identification of
                 otherwise undetectable subpopulations of cells that correspond
                 to different stages during the differentiation of naive T
                 cells into T helper 2 cells. Our approach can be used not only
                 to identify cellular subpopulations but also to tease apart
                 different sources of gene expression heterogeneity in
                 single-cell transcriptomes.",
  journal     = "Nat. Biotechnol.",
  volume      =  33,
  number      =  2,
  pages       = "155--160",
  month       =  feb,
  year        =  2015,
  language    = "en"
}


@ARTICLE{Trapnell2014-xi,
  title       = "The dynamics and regulators of cell fate decisions are
                 revealed by pseudotemporal ordering of single cells",
  author      = "Trapnell, Cole and Cacchiarelli, Davide and Grimsby, Jonna and
                 Pokharel, Prapti and Li, Shuqiang and Morse, Michael and
                 Lennon, Niall J and Livak, Kenneth J and Mikkelsen, Tarjei S
                 and Rinn, John L",
  affiliation = "1] Department of Stem Cell and Regenerative Biology, Harvard
                 University, Cambridge, Massachusetts, USA. [2] The Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
                 [3]. 1] Department of Stem Cell and Regenerative Biology,
                 Harvard University, Cambridge, Massachusetts, USA. [2] The
                 Broad Institute of MIT and Harvard, Cambridge, Massachusetts,
                 USA. [3] Harvard Stem Cell Institute, Harvard University,
                 Cambridge, Massachusetts, USA. [4]. The Broad Institute of MIT
                 and Harvard, Cambridge, Massachusetts, USA. The Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
                 Fluidigm Corporation, South San Francisco, California, USA. 1]
                 Department of Stem Cell and Regenerative Biology, Harvard
                 University, Cambridge, Massachusetts, USA. [2] The Broad
                 Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
                 The Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts, USA. Fluidigm Corporation, South San Francisco,
                 California, USA. 1] Department of Stem Cell and Regenerative
                 Biology, Harvard University, Cambridge, Massachusetts, USA.
                 [2] The Broad Institute of MIT and Harvard, Cambridge,
                 Massachusetts, USA. [3] Harvard Stem Cell Institute, Harvard
                 University, Cambridge, Massachusetts, USA. 1] Department of
                 Stem Cell and Regenerative Biology, Harvard University,
                 Cambridge, Massachusetts, USA. [2] The Broad Institute of MIT
                 and Harvard, Cambridge, Massachusetts, USA. [3] Department of
                 Pathology, Beth Israel Deaconess Medical Center, Boston,
                 Massachusetts, USA.",
  abstract    = "Defining the transcriptional dynamics of a temporal process
                 such as cell differentiation is challenging owing to the high
                 variability in gene expression between individual cells.
                 Time-series gene expression analyses of bulk cells have
                 difficulty distinguishing early and late phases of a
                 transcriptional cascade or identifying rare subpopulations of
                 cells, and single-cell proteomic methods rely on a priori
                 knowledge of key distinguishing markers. Here we describe
                 Monocle, an unsupervised algorithm that increases the temporal
                 resolution of transcriptome dynamics using single-cell RNA-Seq
                 data collected at multiple time points. Applied to the
                 differentiation of primary human myoblasts, Monocle revealed
                 switch-like changes in expression of key regulatory factors,
                 sequential waves of gene regulation, and expression of
                 regulators that were not known to act in differentiation. We
                 validated some of these predicted regulators in a loss-of
                 function screen. Monocle can in principle be used to recover
                 single-cell gene expression kinetics from a wide array of
                 cellular processes, including differentiation, proliferation
                 and oncogenic transformation.",
  journal     = "Nat. Biotechnol.",
  volume      =  32,
  number      =  4,
  pages       = "381--386",
  month       =  apr,
  year        =  2014,
  language    = "en"
}


% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Cannoodt2016-bd,
  title     = "Computational methods for trajectory inference from single-cell
               transcriptomics",
  author    = "Cannoodt, R and Saelens, W and Yvan, S",
  abstract  = "Abstract Recent developments in single-cell transcriptomics have
               opened new opportunities for studying dynamic processes in
               immunology in a high-throughput and unbiased manner. Starting
               from a mixture of cells in different stages of a developmental
               process, unsupervised trajectory inference algorithms aim to
               automatically reconstruct the underlying developmental path that
               cells are following. In this review, we break down the
               strategies ...",
  journal   = "European Journal of Immunology",
  publisher = "Wiley Online Library",
  year      =  2016
}


@ARTICLE{Campbell2016-nl,
  title       = "Order Under Uncertainty: Robust Differential Expression
                 Analysis Using Probabilistic Models for Pseudotime Inference",
  author      = "Campbell, Kieran R and Yau, Christopher",
  affiliation = "Department of Physiology, Anatomy and Genetics, University of
                 Oxford, Oxford, United Kingdom. Wellcome Trust Centre for
                 Human Genetics, University of Oxford, Oxford, United Kingdom.
                 Wellcome Trust Centre for Human Genetics, University of
                 Oxford, Oxford, United Kingdom. Department of Statistics,
                 University of Oxford, Oxford, United Kingdom.",
  abstract    = "Single cell gene expression profiling can be used to quantify
                 transcriptional dynamics in temporal processes, such as cell
                 differentiation, using computational methods to label each
                 cell with a 'pseudotime' where true time series
                 experimentation is too difficult to perform. However, owing to
                 the high variability in gene expression between individual
                 cells, there is an inherent uncertainty in the precise
                 temporal ordering of the cells. Pre-existing methods for
                 pseudotime estimation have predominantly given point estimates
                 precluding a rigorous analysis of the implications of
                 uncertainty. We use probabilistic modelling techniques to
                 quantify pseudotime uncertainty and propagate this into
                 downstream differential expression analysis. We demonstrate
                 that reliance on a point estimate of pseudotime can lead to
                 inflated false discovery rates and that probabilistic
                 approaches provide greater robustness and measures of the
                 temporal resolution that can be obtained from pseudotime
                 inference.",
  journal     = "PLoS Comput. Biol.",
  volume      =  12,
  number      =  11,
  pages       = "e1005212",
  month       =  nov,
  year        =  2016,
  language    = "en"
}


@ARTICLE{Reid2016-yo,
  title       = "Pseudotime estimation: deconfounding single cell time series",
  author      = "Reid, John E and Wernisch, Lorenz",
  affiliation = "MRC Biostatistics Unit, Cambridge CB2 0SR, UK. MRC
                 Biostatistics Unit, Cambridge CB2 0SR, UK.",
  abstract    = "MOTIVATION: Repeated cross-sectional time series single cell
                 data confound several sources of variation, with contributions
                 from measurement noise, stochastic cell-to-cell variation and
                 cell progression at different rates. Time series from single
                 cell assays are particularly susceptible to confounding as the
                 measurements are not averaged over populations of cells. When
                 several genes are assayed in parallel these effects can be
                 estimated and corrected for under certain smoothness
                 assumptions on cell progression. RESULTS: We present a
                 principled probabilistic model with a Bayesian inference
                 scheme to analyse such data. We demonstrate our method's
                 utility on public microarray, nCounter and RNA-seq datasets
                 from three organisms. Our method almost perfectly recovers
                 withheld capture times in an Arabidopsis dataset, it
                 accurately estimates cell cycle peak times in a human prostate
                 cancer cell line and it correctly identifies two precocious
                 cells in a study of paracrine signalling in mouse dendritic
                 cells. Furthermore, our method compares favourably with
                 Monocle, a state-of-the-art technique. We also show using
                 held-out data that uncertainty in the temporal dimension is a
                 common confounder and should be accounted for in analyses of
                 repeated cross-sectional time series. AVAILABILITY AND
                 IMPLEMENTATION: Our method is available on CRAN in the
                 DeLorean package. CONTACT: john.reid@mrc-bsu.cam.ac.uk
                 SUPPLEMENTARY INFORMATION: Supplementary data are available at
                 Bioinformatics online.",
  journal     = "Bioinformatics",
  volume      =  32,
  number      =  19,
  pages       = "2973--2980",
  month       =  "1~" # oct,
  year        =  2016,
  language    = "en"
}


@ARTICLE{Fan2016-af,
  title       = "Characterizing transcriptional heterogeneity through pathway
                 and gene set overdispersion analysis",
  author      = "Fan, Jean and Salathia, Neeraj and Liu, Rui and Kaeser,
                 Gwendolyn E and Yung, Yun C and Herman, Joseph L and Kaper,
                 Fiona and Fan, Jian-Bing and Zhang, Kun and Chun, Jerold and
                 Kharchenko, Peter V",
  affiliation = "Department of Biomedical Informatics, Harvard Medical School,
                 Boston, Massachusetts, USA. Illumina Inc., San Diego,
                 California, USA. Department of Bioengineering, University of
                 California, San Diego, California, USA. Department of
                 Molecular and Cellular Neuroscience, Dorris Neuroscience
                 Center, The Scripps Research Institute, La Jolla, California,
                 USA. Department of Molecular and Cellular Neuroscience, Dorris
                 Neuroscience Center, The Scripps Research Institute, La Jolla,
                 California, USA. Department of Biomedical Informatics, Harvard
                 Medical School, Boston, Massachusetts, USA. Illumina Inc., San
                 Diego, California, USA. Illumina Inc., San Diego, California,
                 USA. Present address: AnchorDx Corporation, International
                 Biotech Island, Guangzhou, Guangdong, China. Department of
                 Bioengineering, University of California, San Diego,
                 California, USA. Department of Molecular and Cellular
                 Neuroscience, Dorris Neuroscience Center, The Scripps Research
                 Institute, La Jolla, California, USA. Department of Biomedical
                 Informatics, Harvard Medical School, Boston, Massachusetts,
                 USA.",
  abstract    = "The transcriptional state of a cell reflects a variety of
                 biological factors, from cell-type-specific features to
                 transient processes such as the cell cycle, all of which may
                 be of interest. However, identifying such aspects from noisy
                 single-cell RNA-seq data remains challenging. We developed
                 pathway and gene set overdispersion analysis (PAGODA) to
                 resolve multiple, potentially overlapping aspects of
                 transcriptional heterogeneity by testing gene sets for
                 coordinated variability among measured cells.",
  journal     = "Nat. Methods",
  volume      =  13,
  number      =  3,
  pages       = "241--244",
  month       =  mar,
  year        =  2016,
  language    = "en"
}

@article{young2010gene,
  title={Gene ontology analysis for RNA-seq: accounting for selection bias},
  author={Young, Matthew D and Wakefield, Matthew J and Smyth, Gordon K and Oshlack, Alicia},
  journal={Genome biology},
  volume={11},
  number={2},
  pages={R14},
  year={2010},
  publisher={BioMed Central}
}

@article{ozturk2016sdpr,
  title={SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis},
  author={Ozturk, Sait and Papageorgis, Panagiotis and Wong, Chen Khuan and Lambert, Arthur W and Abdolmaleky, Hamid M and Thiagalingam, Arunthathi and Cohen, Herbert T and Thiagalingam, Sam},
  journal={Proceedings of the National Academy of Sciences},
  volume={113},
  number={3},
  pages={638--643},
  year={2016},
  publisher={National Acad Sciences}
}

@article{deng2015prmt1,
  title={PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP},
  author={Deng, Xiaolan and Von Keudell, Gottfried and Suzuki, Takehiro and Dohmae, Naoshi and Nakakido, Makoto and Piao, Lianhua and Yoshioka, Yuichiro and Nakamura, Yusuke and Hamamoto, Ryuji},
  journal={Oncotarget},
  volume={6},
  number={34},
  pages={35173},
  year={2015},
  publisher={Impact Journals, LLC}
}

@article{gao2016dual,
  title={The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1},
  author={Gao, Yanyan and Zhao, Yaping and Zhang, Juechao and Lu, Yang and Liu, Xin and Geng, Pengyu and Huang, Baiqu and Zhang, Yu and Lu, Jun},
  journal={Scientific reports},
  volume={6},
  year={2016},
  publisher={Nature Publishing Group}
}

@article{wang2012top2a,
  title={TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy},
  author={Wang, Jiayu and Xu, Binghe and Yuan, Peng and Zhang, Pin and Li, Qing and Ma, Fei and Fan, Ying},
  journal={Breast cancer research and treatment},
  volume={135},
  number={2},
  pages={531--537},
  year={2012},
  publisher={Springer}
}




@ARTICLE{Sever2015-ru,
  title       = "Signal transduction in cancer",
  author      = "Sever, Richard and Brugge, Joan S",
  affiliation = "Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
                 11724. Harvard Medical School, Department of Cell Biology,
                 Boston, Massachusetts 02115.",
  abstract    = "Cancer is driven by genetic and epigenetic alterations that
                 allow cells to overproliferate and escape mechanisms that
                 normally control their survival and migration. Many of these
                 alterations map to signaling pathways that control cell growth
                 and division, cell death, cell fate, and cell motility, and
                 can be placed in the context of distortions of wider signaling
                 networks that fuel cancer progression, such as changes in the
                 tumor microenvironment, angiogenesis, and inflammation.
                 Mutations that convert cellular proto-oncogenes to oncogenes
                 can cause hyperactivation of these signaling pathways, whereas
                 inactivation of tumor suppressors eliminates critical negative
                 regulators of signaling. An examination of the PI3K-Akt and
                 Ras-ERK pathways illustrates how such alterations dysregulate
                 signaling in cancer and produce many of the characteristic
                 features of tumor cells.",
  journal     = "Cold Spring Harb. Perspect. Med.",
  volume      =  5,
  number      =  4,
  month       =  "1~" # apr,
  year        =  2015,
  language    = "en"
}
